Pancreatic Cancer Research

ResearcherUniversity Hospital MagdeburgActive in the last 2 years

Marino Venerito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8581-0974; OpenAlex author ID A5062083405. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 8

  1. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02488-4↗
  2. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Co-author DOI 10.1245/s10434-024-15011-7↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice. Co-author DOI 10.1159/000527692↗
  5. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Co-author DOI 10.1002/cam4.3269↗
  6. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Last author DOI 10.3390/cancers12071955↗
  7. Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Last author DOI 10.1155/2019/5832309↗
  8. Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Last author DOI 10.1159/000487359↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Caspar Franck · 3 shared papers, 2018–2020 · strength 0.37
  2. Peter Malfertheiner MD · 2 shared papers, 2018–2019 · strength 0.24
  3. Wenjie Shi · 1 shared paper, 2024 · strength 0.19
  4. Alexander Link · 1 shared paper, 2024 · strength 0.19
  5. Christoph Kahlert · 1 shared paper, 2024 · strength 0.19
  6. Christiane J. Bruns · 1 shared paper, 2024 · strength 0.19
  7. Ulf D. Kahlert · 1 shared paper, 2024 · strength 0.19
  8. Yue Zhao · 1 shared paper, 2024 · strength 0.19
  9. Dirk Arnold · 1 shared paper, 2022 · strength 0.19
  10. Thomas Theodor Werner Seufferlein · 1 shared paper, 2022 · strength 0.19
  11. Anke Reinacher‐Schick · 1 shared paper, 2022 · strength 0.19
  12. Thorsten Oliver Goetze · 1 shared paper, 2024 · strength 0.16
  13. Salah‐Eddin Al‐Batran · 1 shared paper, 2024 · strength 0.16
  14. Maciej Pech · 1 shared paper, 2020 · strength 0.13
  15. Michael James Overman · 1 shared paper, 2020 · strength 0.11
  16. Alok A. Khorana · 1 shared paper, 2020 · strength 0.11
  17. Eileen Mary O'Reilly · 1 shared paper, 2020 · strength 0.11
  18. Mairead Geraldine McNamara · 1 shared paper, 2020 · strength 0.11
  19. Hanno B. Riess · 1 shared paper, 2020 · strength 0.11
  20. Saroj Vadhan‐Raj · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.